Advanced Courses

ESMO-ESO Courses on Medical Oncology for Medical Students

These annual five-day residential courses enable students to get a full picture of this challenging and interesting professional field before making the choice of their specialisation.

Preceptorship Courses

Apply now to join one of our Preceptorship courses!

Workshops & Courses

ESMO fosters the advancement of cancer research by supporting clinical trials workshops to inspire young oncologists from different disciplines across the globe to become the next generation of active researchers.

Patient Guides

Guides for Patients are designed to assist patients, their relatives and caregivers to better understand the nature of different types of cancer and evaluate the best available treatment choices

Personalised Medicine Explained

Video interviews and articles designed to help patients, policy makers and other non-medical professionals better understand the principles of personalised cancer medicine

Getting the Most out of Your Oncologist

Now available in Romanian, our Guide for Patients with Advanced Cancer is designed for patients, their family members and oncologists.

Designated Centres of Integrated Oncology and Palliative Care

The ESMO Designated Centres of Integrated Oncology and Palliative Care accreditation programme recognises cancer centres which provide comprehensive services in supportive and palliative care as part of their routine care.

EFPIA Disclosure Code

Policy News

Welcome to OncologyPRO, the home of ESMO’s educational and scientific resources, with Guidelines, a comprehensive list of E-Learning modules, Factsheets on biomarkers, slides and webcasts from our educational programme, and more... to support continuing medical education and daily practice!

It is indicated for prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy

On 26 March 2015 the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product netupitant/palonosetron (Akynzeo), indicated for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

The applicant for this medicinal product is Helsinn Birex Pharmaceuticals Ltd.

Akynzeo (an antiemetic and antinauseant, ATC code A04) will be available as a 300 mg/0.50 mg hard capsule. The active substances of Akynzeo in a fixed dose combination are netupitant and palonosetron. Netupitant is a selective antagonist of human substance P/neurokinin 1 (NK1) receptors. Palonosetron is a 5-HT3 receptor antagonist. 5-HT3 receptors have been demonstrated to selectively stimulate the emetic response.

Delayed emesis has been largely associated with the activation of tachykinin family neurokinin 1 (NK1) receptors (broadly distributed in the central and peripheral nervous systems) by substance P. The benefit with Akynzeo is its ability to prevent acute and delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy.

The addition of netupitant to palonosetron leads to an increased therapeutic activity of this fixed dose combination particularly in the delayed phase of emesis. Simplification of therapy by decreasing the number of individual dose units to be taken by the patient may furthermore improve patient compliance.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.